Why Is Quest Diagnostics (DGX) Up 8.2% Since Last Earnings Report?

Quest Diagnostics (DGX) reported robust Q2 2025 results, with adjusted EPS of $2.62 exceeding estimates by 1.9% and revenues rising 15.2% to $2.76 billion, both surpassing consensus. Following these strong financials, DGX shares have gained 8.2% since the last earnings report, outperforming the S&P 500. The company subsequently raised its full-year 2025 revenue guidance to $10.80-$10.92 billion and adjusted EPS to $9.63-$9.83, indicating an optimistic outlook; however, analyst estimates have trended downward in the past month, contributing to a Zacks Rank #3 (Hold).

Analysis

Quest Diagnostics (DGX) delivered a robust second-quarter 2025 performance, exceeding market expectations and prompting a share price increase of 8.2% since the report. The company's adjusted EPS of $2.62 represented an 11.5% year-over-year increase and a 1.9% beat on consensus estimates, while revenues grew 15.2% to $2.76 billion, surpassing forecasts by 1.5%. This top-line growth was primarily driven by a significant 16.3% rise in testing volumes, which successfully offset a marginal 0.4% decline in revenue per requisition. Furthermore, the company demonstrated strong operational efficiency with both gross margin expanding by 61 basis points and adjusted operating margin increasing by 37 basis points. Management signaled confidence by raising its full-year 2025 guidance for both revenue and adjusted EPS, with the new revenue range of $10.80-$10.92 billion now sitting above the consensus estimate. However, a key contradictory signal for investors is that despite these strong results and optimistic company outlook, analyst estimates have trended downward in the past month. This divergence likely contributes to the stock's neutral Zacks Rank #3 (Hold) rating and its poor 'F' score for Momentum, suggesting market sentiment may be more tempered than the company's fundamentals would otherwise imply.

Key Decisions for Investors

• Investors should weigh the company's strong fundamental performance and raised guidance against the cautionary signals of downward-trending analyst estimates and a poor 'F' Momentum score, which suggest the recent 8.2% rally may have already priced in the positive results.
• It is prudent to monitor analyst estimate revisions closely; a reversal of their recent downward trend to align with management's optimistic guidance could serve as a significant catalyst for further stock appreciation.
• For those with a value or income focus, the stock's 'B' grade for value and its 7.31% five-year annualized dividend growth rate could provide a defensive rationale for holding the position, particularly given the 'Hold' rating which implies limited near-term volatility.